RU2755691C2 - Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях - Google Patents

Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях Download PDF

Info

Publication number
RU2755691C2
RU2755691C2 RU2017134857A RU2017134857A RU2755691C2 RU 2755691 C2 RU2755691 C2 RU 2755691C2 RU 2017134857 A RU2017134857 A RU 2017134857A RU 2017134857 A RU2017134857 A RU 2017134857A RU 2755691 C2 RU2755691 C2 RU 2755691C2
Authority
RU
Russia
Prior art keywords
seq
disease
free
cdr2
cdr1
Prior art date
Application number
RU2017134857A
Other languages
English (en)
Russian (ru)
Other versions
RU2017134857A (ru
RU2017134857A3 (https=
Inventor
Грег ДЕЛЬ-ВАЛЬ
Эдуардо ШИФФРИН
Original Assignee
Аб2 Био Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аб2 Био Са filed Critical Аб2 Био Са
Publication of RU2017134857A publication Critical patent/RU2017134857A/ru
Publication of RU2017134857A3 publication Critical patent/RU2017134857A3/ru
Application granted granted Critical
Publication of RU2755691C2 publication Critical patent/RU2755691C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
RU2017134857A 2015-03-05 2016-03-03 Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях RU2755691C2 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP15157742 2015-03-05
EP15157742.6 2015-03-05
EP15158781.3 2015-03-12
EP15158781 2015-03-12
EP15186626.6 2015-09-24
EP15186626 2015-09-24
PCT/EP2016/054524 WO2016139297A1 (en) 2015-03-05 2016-03-03 Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2021126914A Division RU2810206C1 (ru) 2015-03-05 2016-03-03 Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях

Publications (3)

Publication Number Publication Date
RU2017134857A RU2017134857A (ru) 2019-04-09
RU2017134857A3 RU2017134857A3 (https=) 2019-12-23
RU2755691C2 true RU2755691C2 (ru) 2021-09-20

Family

ID=55453181

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017134857A RU2755691C2 (ru) 2015-03-05 2016-03-03 Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях

Country Status (17)

Country Link
US (4) US10882905B2 (https=)
EP (1) EP3265807A1 (https=)
JP (2) JP7274259B2 (https=)
KR (1) KR102511343B1 (https=)
CN (1) CN107660150B (https=)
AU (1) AU2016227644B2 (https=)
CA (1) CA2972689A1 (https=)
CL (1) CL2017002237A1 (https=)
CO (1) CO2017008940A2 (https=)
IL (1) IL253292B2 (https=)
MX (1) MX2017010919A (https=)
MY (1) MY194040A (https=)
PH (1) PH12017501402A1 (https=)
RU (1) RU2755691C2 (https=)
SG (1) SG11201706879UA (https=)
UA (1) UA128752C2 (https=)
WO (1) WO2016139297A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA125204C2 (uk) 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
WO2018119425A2 (en) * 2016-12-22 2018-06-28 Icahn School Of Medicine At Mount Sinai Anti-lilrb3 antibodies and methods of use thereof
IL272635B2 (en) 2017-09-06 2024-02-01 Univ Yale Variants of interleukin-18 and methods of use
US10591492B2 (en) * 2018-03-05 2020-03-17 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
WO2020018364A1 (en) * 2018-07-16 2020-01-23 University Of Hawaii Anti-galectin-9 antibody and methods of use thereof
CN108929382B (zh) * 2018-07-20 2019-10-15 深圳市第三人民医院 一种抗serinc5的抗体及其应用
JP6892180B2 (ja) 2018-12-03 2021-06-23 株式会社ｍＡｂＰｒｏｔｅｉｎ 活性型インターロイキン−１８タンパク質のネオエピトープを認識する抗体、及びその応用
CA3126295A1 (en) * 2019-01-18 2020-07-23 University Health Network Lilrb3-binding molecules and uses therefor
US12594330B2 (en) 2019-06-04 2026-04-07 Regents Of The University Of Minnesota Anti-opioid compounds and methods of making and using same
CN112582058B (zh) * 2019-11-07 2022-04-01 广州医科大学 一种基于空气质量的慢阻肺发病预测方法及系统
US20230173021A1 (en) 2020-05-06 2023-06-08 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) In Respiratory Diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
TW202210511A (zh) * 2020-06-01 2022-03-16 美商阿法羅醫療股份有限公司 涉及il-18抗體之方法及治療
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
KR20230110291A (ko) 2020-11-18 2023-07-21 노파르티스 아게 Nlrc4-gof 염증복합체병증의 치료에 사용하기 위한 이중특이적 항체
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
AU2021479973A1 (en) * 2021-12-20 2024-07-04 Avalo Therapeutics, Inc. Methods and treatment for adult-onset still's disease and systemic-onset juvenile idiopathic arthritis involving antibodies to il-18
CN120737196A (zh) * 2022-01-28 2025-10-03 和径医药科技（上海）有限公司 一种靶向il-18bp的抗体及其应用
US20250179131A1 (en) 2022-03-04 2025-06-05 Ab2 Bio Sa Il-18 binding protein (il-18bp) in the treatment of vexas
WO2023178192A1 (en) * 2022-03-15 2023-09-21 Compugen Ltd. Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer
KR20250133728A (ko) 2023-01-06 2025-09-08 라센 테라퓨틱스, 인코포레이티드 항-il-18bp 항체
WO2024148232A2 (en) 2023-01-06 2024-07-11 Alector Llc Anti-il18 binding protein antibodies and methods of use thereof
WO2026038145A1 (en) 2024-08-13 2026-02-19 Ab2 Bio Sa Il-18 binding protein (il-18bp) and methods of using same
CN119241693B (zh) * 2024-09-29 2025-05-27 华中农业大学 一种抗犬瘟热病毒的基因工程嵌合抗体及应用
CN119192356B (zh) * 2024-09-29 2025-05-27 华中农业大学 识别犬瘟热病毒h蛋白的单克隆抗体、检测试纸条及应用
CN120349409B (zh) * 2025-04-08 2026-03-17 生物岛实验室 Il-18bp纳米抗体及其制备方法与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062285A1 (en) * 2000-02-21 2001-08-30 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors
US20020098185A1 (en) * 2000-10-18 2002-07-25 Sims John E. Methods for treating IL-18 mediated disorders
EA008667B1 (ru) * 2002-10-08 2007-06-29 Арес Трейдинг С.А. Применение цитокина, способного связывать il-18bp и ингибировать активность второго цитокина
US20140004128A1 (en) * 2010-12-20 2014-01-02 Medimmune Limited Anti-il-18 antibodies and their uses
US20140112915A1 (en) * 2012-09-07 2014-04-24 Michael Otto Bardroff IL-18 binding molecules

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2145744T5 (es) 1991-01-18 2008-02-01 Amgen Inc. Procedimientos para tratar las enfermedades inducidas por el factor de necrosis tumoral.
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5635599A (en) 1994-04-08 1997-06-03 The United States Of America As Represented By The Department Of Health And Human Services Fusion proteins comprising circularly permuted ligands
JPH10507643A (ja) 1994-10-21 1998-07-28 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
US5756662A (en) 1995-03-14 1998-05-26 Corixa Corporation Compounds and methods for the detection of T. cruzi infection
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
KR100537558B1 (ko) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 인터류킨-18 결합 단백질
AR022952A1 (es) * 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
TR200502061T2 (tr) * 2000-02-21 2005-08-22 Research Systems Ars Holding N. V. Applied IL-18 inhibitörlerinin kullanımı.
CZ300792B6 (cs) 2000-05-05 2009-08-12 Applied Research Systems Ars Holding N. V. Farmaceutický prostredek
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
CN1326562C (zh) * 2001-01-29 2007-07-18 应用研究系统Ars股份公司 Il－18抑制剂制造治疗和/或预防心脏病的药物的应用
EP1425028B1 (en) 2001-05-16 2009-12-16 Yeda Research And Development Co. Ltd. Use of il-18 inhibitors for the treatement or prevention of sepsis
HRP20030842B1 (hr) * 2001-05-25 2017-06-02 Ares Trading S.A. UPOTREBA IL-18 INHIBITORA ZA LIJEČENJE I PREVENCIJU OZLJEDA CNS-a
BRPI0308663B8 (pt) * 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US7824907B2 (en) 2003-03-11 2010-11-02 Merck Serono Sa Expression vectors comprising the mCMV IE2 promoter
US20080076708A1 (en) 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2011224023C1 (en) 2003-11-12 2013-08-29 Abbvie Inc. IL-18 binding proteins
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
EP1773403B1 (en) 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
AU2005277404A1 (en) 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
AU2006254103B2 (en) 2005-06-03 2012-09-06 Ares Trading S.A. Production of recombinant IL-18 binding protein
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2622332A1 (en) 2005-09-15 2007-03-22 Val-Chum, S.E.C. Methods of diagnosing ovarian cancer and kits therefor
WO2008091588A1 (en) 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
UA125204C2 (uk) * 2013-09-05 2022-02-02 Аб2 Біо Са Застосування il-18-зв'язувального білка (il-18bp) при запальних захворюваннях
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062285A1 (en) * 2000-02-21 2001-08-30 Applied Research Systems Ars Holding N.V. Use of il-18 inhibitors
US20020098185A1 (en) * 2000-10-18 2002-07-25 Sims John E. Methods for treating IL-18 mediated disorders
EA008667B1 (ru) * 2002-10-08 2007-06-29 Арес Трейдинг С.А. Применение цитокина, способного связывать il-18bp и ингибировать активность второго цитокина
US20140004128A1 (en) * 2010-12-20 2014-01-02 Medimmune Limited Anti-il-18 antibodies and their uses
US20140112915A1 (en) * 2012-09-07 2014-04-24 Michael Otto Bardroff IL-18 binding molecules

Also Published As

Publication number Publication date
EP3265807A1 (en) 2018-01-10
JP7818795B2 (ja) 2026-02-24
CO2017008940A2 (es) 2017-11-10
MX2017010919A (es) 2017-12-07
RU2017134857A (ru) 2019-04-09
BR112017017076A2 (en) 2018-04-10
JP2021176860A (ja) 2021-11-11
NZ733897A (en) 2023-11-24
CN107660150B (zh) 2023-10-24
US20210188968A1 (en) 2021-06-24
JP2018513116A (ja) 2018-05-24
KR20170121199A (ko) 2017-11-01
CN107660150A (zh) 2018-02-02
IL253292B1 (en) 2023-01-01
CL2017002237A1 (es) 2018-03-09
MY194040A (en) 2022-11-09
PH12017501402A1 (en) 2018-01-15
US20240190952A1 (en) 2024-06-13
SG11201706879UA (en) 2017-09-28
US10882905B2 (en) 2021-01-05
JP7274259B2 (ja) 2023-05-16
IL253292B2 (en) 2023-05-01
UA128752C2 (uk) 2024-10-16
CA2972689A1 (en) 2016-09-09
WO2016139297A1 (en) 2016-09-09
IL253292A (en) 2017-09-28
US20200377586A1 (en) 2020-12-03
AU2016227644B2 (en) 2022-06-16
US11820817B2 (en) 2023-11-21
US20180127494A1 (en) 2018-05-10
US11926663B2 (en) 2024-03-12
KR102511343B1 (ko) 2023-03-17
RU2017134857A3 (https=) 2019-12-23
AU2016227644A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US20240190952A1 (en) IL-18 Binding Protein (IL-18BP) and Antibodies for Treating Inflammatory Diseases
US20230250164A1 (en) IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases
RU2810206C1 (ru) Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях
CA2922498C (en) Il-18 binding protein (il-18bp) in inflammatory diseases
BR112017017076B1 (pt) Uso de il-18bp
HK1221726B (en) Il-18 binding protein (il-18bp) in inflammatory diseases